尊龙凯时人生就是搏

至今，GenScript的服务及产品已被Cell, Nature, Science, PNAS等1300多家生物医药类杂志引用近万次，处于行业领先水平。NIH、哈佛、耶鲁、斯坦福、普林斯顿、杜克大学等约400家全球著名机构使用GenScript的基因合成、多肽服务、抗体服务和蛋白服务等成功地发表科研成果，再次证明GenScript 有能力帮助业内科学家Make research easy.

Concomitant type I IFN and M-CSF signaling reprograms monocyte differentiation and drives pro-tumoral arginase production.

EBioMedicine. 2019-01; 
TongYuanyuan, ZhouLuyang, YangLimin, GuoPanpan, CaoYanlan, QinF Xiao-Feng, LiuJiang
Products/Services Used Details Operation
… Technology (Erk1/2, #4695; pErk1/2, #4370; CSF1R, #3152; Stat3, #9139; pStat3-Y705, #9145; arginase-1, #93668; pStat1-Y701, #7649; Stat1, #14994), Santa Cruz (GAPDH, #sc-32,233), BD (ARG1, 610,708, for immunofluorescent staining), Genscript (Actin, #A00730) and …

摘要

Type I IFN-based therapies against solid malignancies have yielded only limited success. How IFN affects tumor-associated macrophage (TAM) compartment to impact the therapeutic outcomes are not well understood.

关键词

Anti-tumor immunity，Arginase，M-CSF，Monocyte maturation，Tumor-associated macrophages，Type I